LABELS · 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

Denosumab-BMWO

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-02-05
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Denosumab-bmwo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Denosumab-bmwo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Denosumab-bmwo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Denosumab-bmwo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 ), ( 5.1 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Denosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Denosumab-bmwo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Denosumab-bmwo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Denosumab-bmwo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

Full extracted label fields

application numbers

BLA761404

boxed warning exact

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Denosumab-bmwo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Denosumab-bmwo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. ( 5.1 ) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. ( 5.1 ) Prior to initiating Denosumab-bmwo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Denosumab-bmwo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. ( 2.2 ), ( 5.1 )

brand names

Denosumab-BMWO

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a449553-105c-46a1-bb72-849d8f5b81bd

generic names

DENOSUMAB-BMWO

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

indications and usage exact

1 INDICATIONS AND USAGE Denosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Denosumab-bmwo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Denosumab-bmwo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Denosumab-bmwo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

CELLTRION USA, Inc.

matched search terms

cancer

package ndcs

72606-058-01

product ndcs

72606-058

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2717855

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 374
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Denosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 0

current approval status

not_reconciled

duplicate text group

dup-2622dd81f4a58c9b51b6

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-b5bfe2621787f65ba2e7

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 83
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 39

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 174
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Denosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 )
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 455
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Denosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastat
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 0

current approval status

not_reconciled

duplicate text group

dup-f2d878626bf53e12c667

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-2535496a13dc2c510da2

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 83
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 39

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 255
end exclusive: true
exact text: to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 )
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 175

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · unclassified context

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 545
end exclusive: true
exact text: (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiv
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 56

current approval status

not_reconciled

duplicate text group

dup-6ea007c0335a71a93413

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-d5e973637f20e7a93b0e

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 345
end exclusive: true
exact text: of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 )
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 256

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 681
end exclusive: true
exact text: gh risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 146

current approval status

not_reconciled

duplicate text group

dup-9ed8f7842750555a3747

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-5f70ad1c387e64c8e99c

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 83
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 39

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 481
end exclusive: true
exact text: to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 )
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 346

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · positive indication candidate

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 811
end exclusive: true
exact text: osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Denosumab-bmwo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, de
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 282

current approval status

not_reconciled

duplicate text group

dup-f182ffac934249e22ff4

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-29d0893b36a493d78986

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 83
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 39

qualifier mentions

context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
592
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start
549

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 611
end exclusive: true
exact text: to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 )
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 482

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 6 · positive indication candidate

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1181
end exclusive: true
exact text: ndrogen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Denosumab-bmwo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men wi
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 412

current approval status

not_reconciled

duplicate text group

dup-ebc4ace8c5620f570e51

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-5dcf5b50aef53a8a230c

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 721
end exclusive: true
exact text: is indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 709

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 981
end exclusive: true
exact text: 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Denosumab-bmwo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 612

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1335
end exclusive: true
exact text: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Denosumab-bmwo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history o
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 782

current approval status

not_reconciled

duplicate text group

dup-a62e3c785e3bca8ac463

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-af4117a7fa37c215b5c5

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1135
end exclusive: true
exact text: In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] .
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 982

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1717
end exclusive: true
exact text: rant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Denosumab-bmwo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Denosumab-bmwo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either init
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 936

current approval status

not_reconciled

duplicate text group

dup-62ca6df07caac6d89f38

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-4514c272b847b5a304c2

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 1224
end exclusive: true
exact text: is indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 1212

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1517
end exclusive: true
exact text: 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Denosumab-bmwo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] .
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 1136

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2091
end exclusive: true
exact text: ed as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Denosumab-bmwo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 1318

current approval status

not_reconciled

duplicate text group

dup-39298845ba77203c7961

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-a97a9306aa87a64d56f9

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 1598
end exclusive: true
exact text: is indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 1586

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1891
end exclusive: true
exact text: 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Denosumab-bmwo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 1518

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · risk or warning

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2318
end exclusive: true
exact text: cture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in men at high risk for fracture receivin
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 1692

current approval status

not_reconciled

duplicate text group

dup-1e7300d646a45f09c056

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-db66784ee5759ebc53d8

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2118
end exclusive: true
exact text: High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] .
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 1892

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2589
end exclusive: true
exact text: fined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for B
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 1919

current approval status

not_reconciled

duplicate text group

dup-1e0f79dd1a313f0c695e

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-6d03d9d2678e8da68ead

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 2239
end exclusive: true
exact text: is indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 2227

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2389
end exclusive: true
exact text: 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 2119

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · unclassified context

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2700
end exclusive: true
exact text: y for Prostate Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in women at high risk for fractur
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 2190

current approval status

not_reconciled

duplicate text group

dup-d8f12acbc0fc4e02bd59

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-d808e18285f8a98d4e4b

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2500
end exclusive: true
exact text: In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] .
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 2390

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761404

brand names

Denosumab-BMWO

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2799
end exclusive: true
exact text: fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 2301

current approval status

not_reconciled

duplicate text group

dup-b08cd26f9581e50fce52

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-BMWO

ind-span-d490c3c41b8b88f06979

label id

180d317f-8fa9-4e03-bc3e-756bcfbb4fd6

positive predicate support span

end: 2629
end exclusive: true
exact text: is indicated
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 2617

qualifier mentions

context exact
1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Denosumab-bmwo is indicated as a treatment to in
kind
stage_or_setting
polarity
not_inferred
span
end
2590
end exclusive
true
exact text
Adjuvant Aromatase Inhibitor Therapy for Br
label id
180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start
2547
context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
2755
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start
2712

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2799
end exclusive: true
exact text: 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Denosumab-bmwo is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: 180d317f-8fa9-4e03-bc3e-756bcfbb4fd6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c9515472f40181697b41ce32785e7d80bcd6e31ac65da6ff2ced008bf92290d5
start: 2501

source url

https://api.fda.gov/drug/label.json?search=id%3A%22180d317f-8fa9-4e03-bc3e-756bcfbb4fd6%22

spl effective date

2026-02-05

spl set id

7a449553-105c-46a1-bb72-849d8f5b81bd

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Preserved source evidence · Not medical advice